Supplementary Legends and Figures from Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer

This file includes: (1) legends for Supplementary Figures S1-S8 and Tables S1-S5 and (2) Supplementary Figures S1-S8. Figure S1: Study flow chart for selection of breast cancer patients. Figure S2: Distributions of SCAN normalized gene expression data. Figure S3: Schematic for development of breast cancer-specific RPS values. Figure S4: Variable importance of clinical, pathologic and gene expression features. Figure S5: RPS values in BRCA-mutated clinical breast cancers. Figure S6: RPS associates with adverse clinical-pathologic features. Figure S7: RPS predicts residual cancer burden following neoadjuvant doxorubicinbased chemotherapy in breast cancer. Figure S8: RPS values as a function of hormone receptor and HER2 in breast cancer.